Viral pandemics can quickly overwhelm health system capacity. When a rapid increase in patients with coronavirus disease 2019 (COVID-19) led to ICU bed shortages in Northern Italy1 and elsewhere, clinicians were forced to make difficult ICU resource allocation decisions. Similar surges are now being seen in other parts of the world, including the United States.

What Frameworks Are Available to Support Resource Allocation Decisions?

Ethical frameworks for stewardship of scarce healthcare resources2 share the common dual aims of saving the most lives and maximizing gains in posttreatment length of life.3 However, fulfilling these goals requires clinicians to estimate both the patient’s probability of surviving the acute illness and life expectancy after the episode of critical illness. These estimations are particularly challenging in patients with underlying chronic respiratory diseases, and practical implementation frameworks are lacking.

Recently, several Canadian provinces published frameworks for ICU resource allocation that feature three levels of surge planning.4 Each surge level provides progressively more strict exclusion criteria for ICU admission (and continued ICU care in those already receiving it), as follows:

Level 1—Patients with >80% expected mortality during or in the 6 to 12 months after critical illness

Level 2—Patients with >50% expected mortality during or in the 6 to 12 months after critical illness
Level 3—Patients with >30% expected mortality during or in the 6 to 12 months after critical illness

To help clinicians to approximate these predicted mortalities in patients with chronic respiratory diseases, the Canadian Thoracic Society (CTS) produced a position statement describing corresponding characteristics in COPD, pulmonary fibrosis, cystic fibrosis (CF), and pulmonary arterial hypertension (PAH). This commentary summarizes those findings in an FAQ format. The full position statement, including detailed explanations, rationale, and approach for predicting mortalities can be found online.6

How Did We Estimate Predicted Mortalities in Patients With Chronic Respiratory Conditions?

Disease-based expert groups from across Canada prepared criteria for each respiratory condition independently. Criteria were informed by published survival data, and where possible, complemented by (mostly indirect) data to estimate the impact of critical illness. Accordingly, they are primarily based on expert opinion and should be individualized and supplemented with clinical judgment.

Descriptions for each more severe mortality threshold supersede those in the less severe threshold, such that level 3 descriptions should practically be applied to predict >30% to 50% mortality and level 2 descriptions to predict >50% to 80% mortality.

Cystic Fibrosis

Which cystic fibrosis patients have >80% predicted mortality during or in the 6 to 12 months after critical illness (level 1)?

Patients with FEV₁ of <20% predicted when measured at the time of clinical stability fulfill this criterion.

Which cystic fibrosis patients have >50% predicted mortality during or in the 6 to 12 months after critical illness (level 2)?

Patients with FEV₁ of <20% predicted when measured at the time of clinical stability also fall into this category.

Which cystic fibrosis patients have >30% predicted mortality during or in the 6 to 12 months after critical illness (level 3)?

Patients with FEV₁ of <30% predicted when measured at the time of clinical stability are in this category.

Estimates were derived from the Canadian CF Registry, which captures data on more than 99% of Canadian CF patients. Although FEV₁ of <20% corresponds to an approximately 50% probability of death/transplantation at 1 year (level 2), this criterion was also recommended for level 1, given the additional expected mortality impact of the critical illness itself. The level 3 cutoff was based on the fact that approximately 30% of Canadian CF patients with FEV₁ of <30% will have died or received a transplant by 2 years.

Pulmonary Fibrosis

Which pulmonary fibrosis patients have >80% predicted mortality during or in the 6 to 12 months after critical illness (level 1)?

This level includes patients with:

- FVC <50%-60%; OR
- Diffusing capacity of lung for carbon monoxide (DLCO) <30%-40% predicted; OR
- Chronic supplemental oxygen use at home for >12 hours/day; OR
- Echocardiographic evidence of pulmonary hypertension (estimated right ventricular systolic pressure >50 mm Hg); OR
- Rapidly progressive disease; OR

Institute of the McGill University Health Centre (Dr Bourbeau), McGill University; Toronto General Hospital Research Institute (Dr Chapman), University of Toronto; Sunnybrook Health Sciences Centre, Department of Medicine (Dr Gershon), University of Toronto; Division of Respirology, Department of Medicine (Dr Granton), University Health Network, Sinai Health System, University of Toronto; Department of Medicine (Dr Hambly, Kolb, and Wald), Firestone Institute for Respiratory Health, St. Joseph’s Healthcare, Department of Medicine, McMaster University; Department of Medicine (Dr Hernandez), Dalhousie University; Division of Respirology, Department of Medicine (Dr Mehta), London Health Sciences Centre, Schulich School of Medicine and Dentistry, Western University; Department of Medicine (Dr Mieliczuk), University of Ottawa, Division of Cardiology, University of Ottawa Heart Institute; Pulmonary Hypertension Research Group, Institut universitaire de cardiologie et de pneumologie de Québec, Department of Medicine (Dr Provancher), Université Laval; Adult Cystic Fibrosis Program (Dr Stephenson), St Michael’s Hospital, University of Toronto; Division of Respirology, Department of Medicine (Dr Swiston), University of British Columbia; Division of Medicine (Dr Weatherald), Division of Respirology, L’Hôpital Cardiovasculaire Institute, University of Calgary; Division of Pulmonary Medicine, Department of Medicine (Dr Bhutani), University of Alberta.

CORRESPONDENCE TO: Samir Gupta, MD, St. Michael’s Hospital, Bond 6-042, 30 Bond St, Toronto, ON, M5B 1W8, Canada; e-mail: samir.gupta@unityhealth.to

Copyright © 2020 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.

DOI: https://doi.org/10.1016/j.chest.2020.07.018
History of acute exacerbation of ILD in the last 12 months.

Which pulmonary fibrosis patients have >50% predicted mortality during or in the 6 to 12 months after critical illness (level 2)?

Level 2 also comprises patients with:

- FVC <50%-60%; OR
- DLCO <30%-40% predicted; OR
- Chronic supplemental oxygen use at home for >12 hours/day; OR
- Echocardiographic evidence of pulmonary hypertension (estimated right ventricular systolic pressure >50 mm Hg); OR
- Rapidly progressive disease (>10% decline in FVC over the last 6 months associated with pronounced radiographic and clinical deterioration); OR
- History of AE-ILD in the last 12 months.

*a Prominent right ventricular dilation and hypokinesis preceding COVID-19 infection should also be considered. A conservative measure of 50 mm Hg was selected, given heterogeneous and predominantly retrospective supporting evidence and high prevalence of risk factors for group 2 pulmonary hypertension in ILD patients.

*b10% decline in FVC over the last 6 months associated with pronounced radiographic and clinical deterioration.

Which pulmonary fibrosis patients have >30% predicted mortality during or in the 6 to 12 months after critical illness (level 3)?

Patients meeting the following criteria are considered to be in level 3:

- FVC <50% predicted; AND
- ≥2 hospitalizations within the last 12 months for an acute exacerbation of COPD; AND
- CFS ≥ 5.

We recommend against relying solely on pulmonary function and dyspnea severity (eg, modified Medical Research Council dyspnea scale) to make triage decisions. COPD patients with documented chronic hypoxemia and hypercapnia have higher 1-year mortality.11,12 A history of frequent acute exacerbations of COPD is a strong predictor of mortality.13,14 The CFS is a validated measure of frailty that has been shown to predict mortality in the year after ICU admission.15 Accordingly, we recommend using the CFS to improve prognostication for all surge categories in COPD patients.

PAH

Which PAH patients have >80% predicted mortality during or in the 6 to 12 months after critical illness (level 1)?

PAH patients who are considered to be in level 1 include those with a high-risk profile (Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension [REVEAL] 2.0 score ≥ 9 or high-risk European Respiratory Society/European Society of Cardiology [ESC/ERS] score) while on optimal therapy (at least two oral medications and a parenteral prostacyclin, if eligible).
Which PAH patients have >50% predicted mortality during or in the 6 to 12 months after critical illness (level 2)?

Patients with these conditions are considered to be in level 2:

An intermediate risk profile (REVEAL 2.0 score 7-8 or intermediate-risk ESC/ERS score) while on optimal therapy; AND

Age ≥ 75 years; AND

Either a recent hospitalization for worsening PAH/right heart failure in the past 3 months or the presence of other significant comorbidities (especially chronic renal failure)

Which PAH patients have >30% predicted mortality during or in the 6-12 months after critical illness (level 3)?

Patients meeting the following criteria are considered to be in level 3:

An intermediate-risk profile (REVEAL 2.0 score 7-8 or intermediate-risk ESC/ERS score) while on optimal therapy; AND

Age < 75 years AND

Either a recent hospitalization for worsening PAH/right heart failure in the past 3 months or the presence of other significant comorbidities (especially chronic renal failure)

Poor prognostic factors in PAH include systemic sclerosis origin of PAH; older age; male sex; severe symptoms (New York Heart Association Class III-IV); reduced exercise capacity; comorbidities (eg, renal dysfunction); severe right ventricular dysfunction; and hospitalizations for right heart failure. Available risk prediction tools include the U.S. REVEAL 2.0 risk score16 and the ESC/ERS risk assessment tool.17 We supplemented mortality predictions from these tools with estimates of the effects of critical illness. Our recommendations apply only to PAH (not to pulmonary hypertension groups 2-5).

Given that the pandemic is a rapidly evolving situation, the CTS plans to update this guidance as new information becomes available. We recommend monitoring the CTS website6 for updates.

Acknowledgments

Financial/nonfinancial disclosures: The authors have reported to CHEST the following: S. G. reports grants and personal fees from Ontario Lung Association (OLA), outside the submitted work. J. Ba. reports grants from the Canadian Institutes of Health Research (CIHR), Social Sciences and Humanities Research Council of Canada, OLA, outside the submitted work. K. R. C. reports grants from Amgen, grants and personal fees from Astra-Zeneca, grants and personal fees from Boehringer-Ingelheim (BI), personal fees from CSL Behring, grants and personal fees from GlaxoSmithKline (GSK), grants and personal fees from Grifols, grants and personal fees from Kamar Medicinals, grants from Takeda, grants from Vertex, grants and personal fees from Mereo Biopharma, grants and personal fees from Novartis, grants and personal fees from Sanofi, grants and personal fees from Regeneron, outside the submitted work. J. Bo. reports grants from Canadian Respiratory Research Network, grants and personal fees from AZ, grants and personal fees from BI, grants and personal fees from GSK, grants from CIHR, grants from Respiratory Health Network of the Fonds de la recherche en santé du Québec, personal fees from CTS, personal fees from CHEST, grants and personal fees from Grifols, grants and personal fees from Novartis, grants and personal fees from Trudell, outside the submitted work. A. G. reports grants from CIHR and is a member of the Board of Directors of the Physicians’ Services Inc. Foundation in Ontario. J. G. reports grants from Bayer and Actelion/Janssen, outside the submitted work. A member of steering committee for clinical trials sponsored by United Therapeutics and Actelion/Janssen, outside the submitted work. N. H. reports grants and personal fees from Actelion, Bayer, BI, and Hoffman-La Roche Ltd. and personal fees from Novartis, outside the submitted work. P. H. reports grants from CIHR, Lung Association of Nova Scotia, Nova Scotia Health Authority Research Fund, AZ, BI, Cytomediqa, Grifols, Respi Vert, and Vertex; and personal fees from Actelion, AZ, BI, GSK, Novartis, Sanofi, Trudell, outside the submitted work. M. K. reports grants and personal fees from BI and Hoffman-La Roche Ltd., GSK, Gilead and Prometic, grants from Actelion, Respi Vert, Alkermes and Pharmacis, and personal fees from Genoa, Indalo and Third Pole, outside the submitted work. S. M. reports grants from Heart and Stroke Foundation of Ontario/Canada, OLA, Academic Medical Organization of Southwest Ontario, CIHR, Bell-Mephenoxon, Eiger, Reata, and United Therapeutics; grants and personal fees from Actelion-Janssen and Bayer, outside the submitted work. L. M. reports grants from AZ, Bayer, Janssen, and personal and speaker fees from AZ, Bayer, Janssen, Novartis, outside the submitted work. S. P. reports grants from AZ, Janssen and Resverlogix, outside the submitted work. A. L. S. reports grants from Cystic Fibrosis Canada, US Cystic Fibrosis Foundation; and personal fees from Vertex Pharmaceuticals and Cystic Fibrosis Canada, outside the submitted work. I. S. reports grants and personal fees from Actelion, Johnson & Johnson, Bayer, Unither, and United Therapeutics, outside the submitted work. D. E. T. reports grants from Bayer, BI, Celoxis, Corbus, Proteostasis, Stryyx and Vertex Pharmaceuticals and personal fees from Horizon, Proteostasis, Vertex, outside the submitted work. J. Wa. reports personal fees from GSK, grant from Fisher & Paykel, outside the submitted work. J. We. reports grants from CIHR, Lung Association of Alberta and NWT, Heart & Stroke Foundation of Canada, European Respiratory Society, CTS, Canadian Vascular Network; grants and personal fees from Actelion; grants and personal fees from Janssen; personal fees from Novartis and Bayer, outside the submitted work. M. B. reports personal fees and grants from AZ, BI, GSK, Novartis, Sanofi-Genzyme, CIHR, Alberta Innovates Health Solutions, outside the submitted work. None declared (N. T. V.)

Other contributions: We acknowledge the Lung Health Foundation for supporting the COPD estimates in this statement.

References


